Vildagliptin: optimal control in type 2 diabetes mellitus treatment

QR Code

Vildagliptin: optimal control in type 2 diabetes mellitus treatment

Incretin hormones are important for normal pancreatic islet function and glucose homeostasis. Sensitivity to glucose of the α- and β-cells of the pancreas is diminished in type 2 diabetes mellitus (T2DM), leading to impaired insulin secretion, insulin resistance due to elevated glucagon levels in hy...

Description complète

Enregistré dans:

Détails bibliographiques
Auteur principal:	Alexander Sergeevich Ametov
Format:	article
Langue:	EN RU
Publié:	Endocrinology Research Centre 2015
Sujets:	diabetes mellitus glucagon-like peptide-1 glucose-dependent insulinotropic polypeptide insulin resistance vildagliptin efficacy safety Nutritional diseases. Deficiency diseases RC620-627
Accès en ligne:	https://doaj.org/article/2ee27128d50d4f50b47926bff32edca5
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

New glance at pathogenesis of type 2 diabetes mellitus: incretin and antiincretin systems.
par: Ekaterina Alekseevna Shestakova
Publié: (2011)

The role of incretin-based therapies in the management of type 2 diabetes mellitus: perspectives on the past, present and future
par: Juris J. Meier
Publié: (2019)

Incretins today: multiple effects and therapeutic potential
par: Oksana V. Tsygankova, et autres
Publié: (2019)

The associations of incretin hormone concentration with gestational diabetes mellitus
par: Tatiana V. Saprina, et autres
Publié: (2016)

EDGE study in Russian Federation: efficacy and safety of vildagliptine in comparison with other oral antidiabetic agents in patients with type 2 diabetes mellitus
par: Gagik Radikovich Galstyan
Publié: (2013)

Pharmalogical effects and results of clinical trials of the first incretinomimetic exenatide
par: Alexander Sergeevich Ametov, et autres
Publié: (2011)

The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect
par: Enrique Z. Fisman, et autres
Publié: (2021)

The efficacy of therapy with DPP-4 inhibitors combined with insulin in patients with type 2 diabetes mellitus
par: Alexander Sergeevich Ametov, et autres
Publié: (2011)

Evolution of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes
par: Gagik R. Galstyan, et autres
Publié: (2017)

Clinical implementetion of vildagliptin: data from recent studies comparing incretin-based medications
par: Elena Valer'evna Biryukova
Publié: (2014)

Nephroprotective potential of glucagon-like peptide-1 receptor agonists
par: Minara S. Shamkhalova, et autres
Publié: (2020)

Vildagliptin: the first innovative DDP-4 inhibitor
par: Edvin Villkhauer
Publié: (2010)

The role of human glucagon-like peptide-1 analog in therapy of type 2 dianetes mellitus
par: Marina Vladimirovna Shestakova
Publié: (2010)

Once-weekly administration of dulaglutide, a glucagon-like peptide-1 receptor agonist, as monotherapy and combination therapy: review of the AWARD studies
par: Marina V. Shestakova, et autres
Publié: (2017)

Dipeptidylpeptidase-4 inhibitors in the treatment of diabetes mellitus. Possibilities of cardioprotection
par: Elena Nikolaevna Trunina, et autres
Publié: (2011)

Results of a clinical trial of the efficacy and safety of vildagliptin and metformin fixed combination in real clinical practice in Russia (MASTER study)
par: N. A. Demidov, et autres
Publié: (2021)

Possible applications of gliptins (dipeptidyl peptidase-4 inhibitors) in patients with type 2 diabetes mellitus on the various modes of insulin therapy
par: Gagik Radikovich Galstyan, et autres
Publié: (2015)

When basal insulin is not enough: successful strategies for insulin intensification in patients with type 2 diabetes mellitus
par: Elena V. Buryukova, et autres
Publié: (2017)

First Russian DPP-4 inhibitor Gosogliptin comparing to Vildagliptin in type 2 diabetes mellitus patients
par: Karina Oganesovna Galstyan, et autres
Publié: (2016)

Diabetes and obesity. The role of agonists glucagon-like peptide-1 of in the treatment of type 2 diabetes
par: Nina A. Petunina, et autres
Publié: (2018)

Mechanisms of cardiovascular protection of non-insulin antidiabetic medications
par: Angelo Avogaro
Publié: (2018)

Sakharnyy diabet i gormonal'naya enterologiya: put' v prekrasnoe daleko?
par: Andrey Alexeevich Aleksandrov
Publié: (2011)

Immunohystochemical study of the largest islets of human pancreas in aging and diabetes mellitus: perspectives for the transplantation
par: Alexandra Evgen'evna Proshchina, et autres
Publié: (2013)

A review of insulin lispro for the treatment of patients with type 2 diabetes mellitus
par: Marina V. Shestakova, et autres
Publié: (2016)

Mechanisms of neuroprotective action of incretin mimetics
par: Timur Dmitrievich Vlasov, et autres
Publié: (2016)

Quality of glycemic control in assessment of the requirement for insulin in patients with type 2 diabetes and comorbid pathology
par: Irina A. Kurnikova, et autres
Publié: (2018)

Statin use and risk of diabetes mellitus
par: Oksana Mikhailovna Drapkina, et autres
Publié: (2012)

Individual stepwise intensification of insulin analogue therapy in type 2 diabetes mellitus
par: Alexander Sergeevich Ametov, et autres
Publié: (2012)

Hormonal, metabolic and genetic predictors of metformin efficacy in patients with diabetes mellitus and cancer
par: Lev Mikhaylovich Bershteyn, et autres
Publié: (2014)

What are new opportunities for clinical practice the VERIFY study opens and which values for native diabetes patients? Joint conclusion on the advisory board results. November 6, 2019
par: Marina V. Shestakova, et autres
Publié: (2020)

To Assess Liraglutide’s Therapeutic Effect in Patients with Type 2 Diabetes Mellitus Using Flash Glucose Monitoring System
par: Yin J, et autres
Publié: (2021)

Insulin resistance in pathogenesis of type 2 diabetes mellitus
par: Alexander Yur'evich Mayorov
Publié: (2011)

Incretin-based therapy: renal effects
par: Anton Ivanovich Korbut, et autres
Publié: (2016)

Overcoming marked insulin resistance in a patient with type 2 diabetes mellitus by means of insulin pumptherapy
par: Ekaterina Viktorovna Artemova, et autres
Publié: (2012)

Telomere length and vascular wall in patients with Type 2 Diabetes Mellitus
par: Ekaterina Nailyevna Dudinskaya, et autres
Publié: (2014)

The effects of structured self-monitoring of blood glucose on therapeutic effectiveness and adherence in patients with type 2 diabetes mellitus initiating insulin treatment
par: Lyudmila Alexandrovna Suvorova, et autres
Publié: (2013)

Clinical and psychological aspects of hypoglycemia in patients with diabetes mellitus
par: Olga Georgievna Mel'nikova, et autres
Publié: (2010)

Functional activity and peripheral insulin resistance in patients with different types of onset of diabetes mellitus
par: Tatiana Vasil'evna Nikonova, et autres
Publié: (2012)

Liraglutide ameliorates nonalcoholic fatty liver disease in diabetic mice via the IRS2/PI3K/Akt signaling pathway
par: Yang P, et autres
Publié: (2019)

Vildagliptin and its role in the treatment of diabetes mellitus
par: Yury Shavkatovich Khalimov
Publié: (2010)